Rigel Pharma (RIGL) Posts Smaller than Expected Q3 Loss

Rigel Pharma (NASDAQ: RIGL) reported Q3 EPS of ($0.24), $0.03 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $0 versus the consensus estimate of $430 thousand.

As of September 30, 2014, Rigel had cash, cash equivalents and available for sale securities of $157.7 million, compared to $212.0 million as of December 31, 2013. Rigel expects to end 2014 with cash and investments in excess of $135.0 million, which is expected to be sufficient to fund operations into the third quarter of 2016.

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Velan Inc.: Announcement